Bhaskar Anand - May 15, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role: SVP, Chief Accounting Officer
Signature: /s/ Tracy Herson, attorney-in-fact
Stock symbol: RETA
Transactions as of: May 15, 2023
Transactions value $: -$92,714
Form type: 4
Date filed: 5/17/2023, 04:26 PM
Previous filing: Mar 8, 2023
Next filing: Jun 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RETA	Class A common stock	Sale	-$81.7K	-950	-3.55%	$85.98	25.8K	May 15, 2023	Direct	F1, F2
transaction	RETA	Class A common stock	Sale	-$11K	-136	-0.53%	$81.10	25.7K	May 16, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.92 to $86.00 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.92 to $86.00 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.